Former Allogene CFO Eric Schmidt talks about his new role at Cantor and the future of cell therapies
Cantor Fitzgerald announced on Tuesday that Eric Schmidt and Josh Schimmer are joining its biotech research group.
Schimmer is a former senior managing director of Evercore ISI’s biotech research team, while Schmidt was most recently the chief financial officer at cell therapy company Allogene. Prior to Allogene, Schmidt spent 20 years as an analyst at Cowen.
Endpoints chatted briefly over Zoom with Schmidt about Cantor’s biotech equity research and the future of cell and gene therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.